A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer

Deborah Citrin, Kevin Camphausen, Bradford J. Wood, Martha Quezado, John Denobile, James F. Pingpank, Richard E. Royal, H. Richard Alexander, Geoffrey Seidel, Seth M. Steinberg, Yvonne Shuttack, Steven K. Libutti

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: The purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade™ injections combined with concurrent capecitabine and radiotherapy in the treatment of patients with locally advanced rectal cancer. Methods: Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50.4-54 Gy in combination with capecitabine 937.5 mg/m2 p.o. b.i.d. TNFerade™ at a dose of 4 × 1010 particle units was injected into the rectal tumor on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation. Results: Nine patients were enrolled in this pilot trial. The stage was cT2 in 2 patients, cT3 in 6 patients, cT4 in 1 patient, N- in 7 patients and N+ in 2 patients. Eight patients completed all treatments. Grade 3 hematologic toxicity was observed in 2 patients. There was no toxicity directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 patients. Conclusions: This study demonstrates the feasibility of weekly intratumoral TNFerade™ injections during chemoradiotherapy for locally advanced rectal cancer. Pathologic responses with this combination compare favorably to published rates.

Original languageEnglish (US)
Pages (from-to)382-388
Number of pages7
JournalONCOLOGY (United States)
Volume79
Issue number5-6
DOIs
StatePublished - Apr 2011

Fingerprint

Feasibility Studies
Rectal Neoplasms
Radiotherapy
Therapeutics
Injections
Capecitabine
Chemoradiotherapy

Keywords

  • Neoadjuvant
  • Radiation
  • Rectal carcinoma
  • TNFerade™

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. / Citrin, Deborah; Camphausen, Kevin; Wood, Bradford J.; Quezado, Martha; Denobile, John; Pingpank, James F.; Royal, Richard E.; Alexander, H. Richard; Seidel, Geoffrey; Steinberg, Seth M.; Shuttack, Yvonne; Libutti, Steven K.

In: ONCOLOGY (United States), Vol. 79, No. 5-6, 04.2011, p. 382-388.

Research output: Contribution to journalArticle

Citrin, D, Camphausen, K, Wood, BJ, Quezado, M, Denobile, J, Pingpank, JF, Royal, RE, Alexander, HR, Seidel, G, Steinberg, SM, Shuttack, Y & Libutti, SK 2011, 'A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer', ONCOLOGY (United States), vol. 79, no. 5-6, pp. 382-388. https://doi.org/10.1159/000323488
Citrin, Deborah ; Camphausen, Kevin ; Wood, Bradford J. ; Quezado, Martha ; Denobile, John ; Pingpank, James F. ; Royal, Richard E. ; Alexander, H. Richard ; Seidel, Geoffrey ; Steinberg, Seth M. ; Shuttack, Yvonne ; Libutti, Steven K. / A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. In: ONCOLOGY (United States). 2011 ; Vol. 79, No. 5-6. pp. 382-388.
@article{4003321ee3034823a94be140021146d6,
title = "A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer",
abstract = "Objective: The purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade™ injections combined with concurrent capecitabine and radiotherapy in the treatment of patients with locally advanced rectal cancer. Methods: Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50.4-54 Gy in combination with capecitabine 937.5 mg/m2 p.o. b.i.d. TNFerade™ at a dose of 4 × 1010 particle units was injected into the rectal tumor on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation. Results: Nine patients were enrolled in this pilot trial. The stage was cT2 in 2 patients, cT3 in 6 patients, cT4 in 1 patient, N- in 7 patients and N+ in 2 patients. Eight patients completed all treatments. Grade 3 hematologic toxicity was observed in 2 patients. There was no toxicity directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 patients. Conclusions: This study demonstrates the feasibility of weekly intratumoral TNFerade™ injections during chemoradiotherapy for locally advanced rectal cancer. Pathologic responses with this combination compare favorably to published rates.",
keywords = "Neoadjuvant, Radiation, Rectal carcinoma, TNFerade™",
author = "Deborah Citrin and Kevin Camphausen and Wood, {Bradford J.} and Martha Quezado and John Denobile and Pingpank, {James F.} and Royal, {Richard E.} and Alexander, {H. Richard} and Geoffrey Seidel and Steinberg, {Seth M.} and Yvonne Shuttack and Libutti, {Steven K.}",
year = "2011",
month = "4",
doi = "10.1159/000323488",
language = "English (US)",
volume = "79",
pages = "382--388",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer

AU - Citrin, Deborah

AU - Camphausen, Kevin

AU - Wood, Bradford J.

AU - Quezado, Martha

AU - Denobile, John

AU - Pingpank, James F.

AU - Royal, Richard E.

AU - Alexander, H. Richard

AU - Seidel, Geoffrey

AU - Steinberg, Seth M.

AU - Shuttack, Yvonne

AU - Libutti, Steven K.

PY - 2011/4

Y1 - 2011/4

N2 - Objective: The purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade™ injections combined with concurrent capecitabine and radiotherapy in the treatment of patients with locally advanced rectal cancer. Methods: Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50.4-54 Gy in combination with capecitabine 937.5 mg/m2 p.o. b.i.d. TNFerade™ at a dose of 4 × 1010 particle units was injected into the rectal tumor on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation. Results: Nine patients were enrolled in this pilot trial. The stage was cT2 in 2 patients, cT3 in 6 patients, cT4 in 1 patient, N- in 7 patients and N+ in 2 patients. Eight patients completed all treatments. Grade 3 hematologic toxicity was observed in 2 patients. There was no toxicity directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 patients. Conclusions: This study demonstrates the feasibility of weekly intratumoral TNFerade™ injections during chemoradiotherapy for locally advanced rectal cancer. Pathologic responses with this combination compare favorably to published rates.

AB - Objective: The purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade™ injections combined with concurrent capecitabine and radiotherapy in the treatment of patients with locally advanced rectal cancer. Methods: Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50.4-54 Gy in combination with capecitabine 937.5 mg/m2 p.o. b.i.d. TNFerade™ at a dose of 4 × 1010 particle units was injected into the rectal tumor on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation. Results: Nine patients were enrolled in this pilot trial. The stage was cT2 in 2 patients, cT3 in 6 patients, cT4 in 1 patient, N- in 7 patients and N+ in 2 patients. Eight patients completed all treatments. Grade 3 hematologic toxicity was observed in 2 patients. There was no toxicity directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 patients. Conclusions: This study demonstrates the feasibility of weekly intratumoral TNFerade™ injections during chemoradiotherapy for locally advanced rectal cancer. Pathologic responses with this combination compare favorably to published rates.

KW - Neoadjuvant

KW - Radiation

KW - Rectal carcinoma

KW - TNFerade™

UR - http://www.scopus.com/inward/record.url?scp=79953062841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953062841&partnerID=8YFLogxK

U2 - 10.1159/000323488

DO - 10.1159/000323488

M3 - Article

C2 - 21447969

AN - SCOPUS:79953062841

VL - 79

SP - 382

EP - 388

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 5-6

ER -